Press Releases

Press Releases

    Date Title View
    05/06/21
    Summary ToggleHorizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference
    PDF Version
    05/06/21
    Summary ToggleNew Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation
    PDF Version
    05/06/21
    Summary ToggleHorizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen’s Association 2021 Luminary
    PDF Version
    05/05/21
    Summary ToggleHorizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.
    04/27/21
    Summary ToggleHorizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide
    PDF Version
    04/16/21
    Summary ToggleNew Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    04/16/21
    Summary ToggleNew Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology
    PDF Version
    04/12/21
    Summary ToggleHorizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For®
    PDF Version
    04/08/21
    Summary ToggleHorizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021
    PDF Version
    04/07/21
    Summary ToggleRECIPE Randomized Controlled Trial Data Published in Arthritis & Rheumatology Show Higher Response Rates Using KRYSTEXXA® (pegloticase injection) with the Immunomodulator Mycophenolate Mofetil
    PDF Version
    Displaying 1 - 10 of 576 results